Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2019 Earnings Presentation
16 slides from Alkem Laboratories's earnings presentation, Feb 8, 2019
Slide 1: Cover letter to stock exchanges
<0> ALKEM ALKEM LABORATORIES LTD. To aieve value driven leadership in Health Care Industry and beyond... Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Through nite Indian ch Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Quality that is cares Email : contact@alkem.com Web
Slide 2: Press Release: Alkem reports Q3FY19 and 9MFY19 Results
<a> ALKEM 41(04% it4 ViSat ALKEM LABORATORIES LTD. To achieve value driven leadership in are Industry and bey Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, CCo Indian Health Through, finite Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Quality that is Email : contact@alk
Slide 3: Operational Highlights: India Business
<8> ALKEM in d•• ALKEM LABORATORIES LTD. To achieve value driven leadership bey Health Care Industry and Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Through nite Indian Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Quality that is infi es Email : contact@alkem.com Webs
Slide 4: International Markets and R&D Investments
<8> ALKEM ALKEM LABORATORIES LTD. beyon To achieve value driven leadership in ealth Care Industry and Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Through finite Indian H Lower Pare!, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 that is inf Quality s Email : contact@alkem.com Websi
Slide 5: Investor Presentation Q3FY19 – February 8, 2019
Investor Presentation Q3FY19 – February 8, 2019
Slide 6: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 7: Key Highlights of Q3FY19 and 9MFY19
Key Highlights of Q3FY19 and 9MFY19 • India Business: Company’s India sales registered 0.7% YoY decline in Q3FY19 on account of ban on select FDC products, slower growth in anti-infective and gastro-intestinal market and de-growth in trade generic business due to tightening of credit terms • Company
Slide 8: Key Financial Highlights – Q3FY19 (Consolidated)
Key Financial Highlights – Q3FY19 (Consolidated) All figures in Rs mn Revenue from Operations India sales 12,567 YoY: (0.7)% 12,475 19,250 17,412 Q3FY18 Q3FY19 International sales 6,532 4,659 Q3FY18 Q3FY19 Q3FY18 Q3FY19
Slide 9: Key Financial Highlights – Q3FY19 (Consolidated)
Key Financial Highlights – Q3FY19 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin YoY: (1.1)% 11,148 11,020 3,605 3,118 64.0% 57.2% 20.7% 16.2% Q3FY18 Q3FY19 Q3FY18 Q3FY19 PBT (before Minority Interest) PAT (after Minority Interest) 3,324 2,025 2,581 1,716
Slide 10: India Business
India Business India Business: Q3FY19 Sales of Rs.12,475 million (0.7% YoY decline) • YoY decline in India sales during Q3FY19 was mainly on account of ban on select FDC products, de-growth in Company’s trade generic business due to tightening of credit terms, slower growth in the anti-infective mar
Slide 11: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in 9MFY19 -1 Established therapeutic Market rank 1 3 3 5 areas of Alkem 17.8% 13.9% 13.8% 13.0% 7.8% 9.0% 9.1% 5.8% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients
Slide 12: US Business
US Business US Business: Q3FY19 Sales of Rs.5,182 million (44.3% growth YoY) • US sales contributed 27.3% to total sales in Q3FY19 • Growth in the US business was driven by combination of new product launches and market share gains in the existing products. Depreciation of INR against USD also helpe
Slide 13: Update on the US FDA inspection
Update on the US FDA inspection In the month of January and February 2019, the US FDA conducted inspections at the Company’s formulation manufacturing facilities located at Daman (India) and St. Louis (US). At the end of the inspection, no Form 483 was issued for the Daman facility, while the St. Lo
Slide 14: Other International Business
Other International Business Other International Business: Q3FY19 Sales of Rs.1,349 million (26.4% YoY growth) • Other International Market sales contributed 7.1% to total sales in Q3FY19 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Australia and
Slide 15: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2018 Non-Institution, 26.30% Promoter & Institution, Promoter Group, 7.73% 65.98% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bo
Slide 16: Thank You
Thank You DP ar @.